AstraZeneca’s decision to revive its commitment to the UK with a £200 million investment in Cambridge should be recognised as a significant vote of confidence in both the city and the wider UK life sciences sector.
RELATED ARTICLES
This news story is available exclusively to CoStar subscribers.
Watch the video to learn how you can access industry leading CRE news and the data analytics you need to drive success.
This news story is available exclusively to CoStar subscribers.
Ready to Learn More?
Sign Up For a Personalized Demo.
Sign Up For a Demo To Learn More.
Already A Subscriber? Sign In